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Abstract  1 
Subacute neuroregression in association with raised neopterin and overexpression of interferon 2 
stimulated genes (ISGs) could indicate a type 1 interferonopathy. Here we describe a novel 3 
immunotherapy-responsive, clinico-immunological and imaging phenotype with evidence of innate 4 
immune activation. Three children (patient 1: 22-month-old boy; patient 2: 5-year-old girl; patient 3: 4-5 
year-old girl) presented with asymmetric bilateral mixed dystonia and spasticity, regression in language 6 
(expressive more than receptive) and bulbar symptoms with no evidence of seizures.  Symptoms 7 
evolved over several weeks to months. Brain MRI changes mimicked cerebral atrophy, initially 8 
asymmetric. CSF revealed raised neopterins. Blood RNA assay showed abnormal overexpression of 9 
ISGs and transient raised alanine aminotransferase (ALT). Importantly, all three children were treated 10 
with intravenous methylprednisolone and immunoglobulin with significant and sustained improvement in 11 
their motor and language function, and normalisation of imaging.  Immune-mediated encephalitis can 12 
masquerade as subacute neuroregression. 13 
 14 
15 
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 3 
Introduction 1 
Type I interferonopathies are a novel group of multiple monogenic autoinflammatory and autoimmune 2 
disorders presenting with early-onset systemic and organ-specific disease and characterized by genetic 3 
upregulation of the antiviral type I interferon axis with heterogeneous and expanding phenotypes. To 4 
date 18 different causative genes have been identified1. This was first described as the classical 5 
phenotype of Aicardi-Goutières syndrome (AGS), a genetic leukoencephalopathy mimicking a 6 
congenital infection and characterized by progressive cerebral atrophy, basal ganglia calcification and 7 
lymphocytosis.  8 
 9 
Interferons play an important role in the immune response against viral infections. The secretion of 10 
these cytokines is normally induced by activation of recognition receptors of the innate immune system 11 
after exposure to viral nucleic acids1. Abnormalities in these test results can also occur in acquired 12 
conditions such as autoimmune disorders and viral infections although not typically seen in antibody-13 
mediated encephalopathies2,3. Until recently, it was difficult to directly measure type 1 interferon (IFN) 14 
concentrations in biological samples. IFN activity is determined through IFN signature, meaning the 15 
mRNA quantification of genes that are induced by IFN activity - interferon-stimulated genes (ISGs). A 16 
neurological syndrome associated with raised neopterin and abnormal activation of ISGs could indicate 17 
a type I interferonopathy.2 18 
 19 
Here, we describe three children who presented with subacute motor and bulbar regression, mildly high 20 
alanine aminotransferase (ALT), imaging appearances mimicking cerebral atrophy and an abnormal 21 
ISGs who improved with immunotherapy suggestive of an acquired disorder. Written informed consent 22 
for publication of the case description and the videos was obtained for all patients.   23 
 24 
Case 1: 25 
A previously well 22-month-old boy with a normal antenatal and developmental profile, presented with 26 
fluctuating left sided hemiparesis. Five months later, following an intercurrent illness, he developed an 27 
additional right-sided weakness and was unable to sit (Video 1). His speech regressed to 5 single 28 
words only and he developed swallowing difficulties. There was no history of seizures, behavioural 29 
deterioration or sleep problems.  On examination, he had mixed dystonia and spasticity with increased 30 
tone of all limbs, more marked in the lower limbs. There was sustained clonus on the left.  He had 31 
increased reflexes bilaterally (left more than right) with up-going plantars. There was mild facial 32 
weakness on the left side but full range of ocular movements. Head circumference was normal. There 33 
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was no hepatosplenomegaly. Serial magnetic resonance imaging (MRI) of the brain demonstrated 1 
progressive initially right hemispheric and subsequently evolving to global symmetric cerebral volume 2 
loss (Figure 1-A). At 18 months from clinical presentation he was started on six weekly pulses 3 
intravenous Methylprednisolone (IVMP, 30mg/kg/d), followed by six weekly IV Immunoglobulin (IVIG, 4 
2g/kg). IVIG treatment is ongoing. This treatment resulted in improvement mainly in his fine motor and 5 
non-verbal communication skills. Although less impressive, he showed improvement in his gross motor 6 
skills and speech as well. He is now able to sit unsupported and is slowly gaining new vocabulary 7 
(Video 1). Two years after treatment initiation brain MRI showed complete reversal of previous changes 8 
and no other abnormalities. (Figure 1-B). 9 
 10 
 11 
Case 2: 12 
A previously well 5-year-old girl with a normal antenatal and developmental profile, presented with a 13 
subacute onset over three months of left sided weakness, frequent falls and difficulties climbing stairs. 14 
She was also unable to raise her left arm and had problems dressing and undressing.  Her right side 15 
was also affected and her handwriting deteriorated.  Her speech deteriorated and she developed 16 
swallowing difficulties with excessive drooling.  There was no cognitive regression, sleep disturbance or 17 
history of seizures. On examination, her speech was dysarthric. She had a mixture of spasticity and 18 
dystonia with lower limbs more affected than upper limbs and left side more than right. Her tone was 19 
increased bilaterally with sustained clonus on the left and upgoing plantars bilaterally. Head 20 
circumference was normal. Brain MRI demonstrated generalized volume loss more marked in the right 21 
cerebral hemisphere (Figure 1-C). Brain biopsy findings are summarised in Figure 2. At 12 months from 22 
onset the patient was treated with four cycles of pulse IVMP (30mg/kg/d for 5 days) and IVIG (2g/kg) 23 
three to four months apart. This resulted in significant improvement in her movement disorder and in all 24 
domains of function (gross motor, fine motor and speech) (Video 2). Repeated imaging three years 25 
after treatment showed normalisation of MRI appearances (Figure 1-D). 26 
 27 
Case 3: 28 
A previously well 4-year-old girl with mild gross motor developmental delay (walked independently at 29 
the age of 21 months), presented with a progressive one-year history of frequent trips and falls, 30 
difficulty climbing stairs, and progressive walking difficulty needing the aid of a wheelchair for outdoors 31 
(Video 3). There was also five-month history of speech regression; initially slurred incomprehensible 32 
words, followed by  complete loss of expressive language. She had dysphagia with choking on solids 33 
and liquids and drooling. Behavioural difficulties were also reported with frequent angry outbursts and 34 
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 5 
peer relationship problems. There was no history of seizures. On examination, her tone was increased 1 
in the lower limbs with mixed spasticity and dystonia, right being worse than left and bilateral upgoing 2 
plantars. She walked with a wide gait with both her knees hyperextended. There was drooling but no 3 
cranial nerve abnormalities. Head circumference was below the 0.4th centile (no previous 4 
measurements available for comparison). No hepatosplenomegaly was found. MRI brain showed mild 5 
global cerebral volume loss mimicking atrophy (Figure 1-E). At 15 months from onset she had one 6 
course of three days IVMP (30mg/kg/d), followed by IVIG (2g/kg) cycles, five courses over 20 months. 7 
Marked improvement in her lower limb tone, with gain in both motor and expressive language skills, 8 
was observed. A repeat MRI at 13 months after treatment initiation showed reversal of previous 9 
changes (Figure 1-F). Currently, she is able to climb stairs unaided (Video 3), her speech is clear and 10 
she can produce three to four word sentences. 11 
 12 
Investigations, treatment and outcomes for all patients are summarized in Table 1. 13 
All 3 patients were investigated for a range of infective, inflammatory and neurometabolic aetiologies, 14 
none of which were identified. CSF in all patients showed no cells, normal protein and raised neopterin 15 
at 355, 200 and 151nmol/L (normal range 7-65) respectively. Repeated CSF analysis showed 16 
normalization of neopterins in patient 2 (29 nmol/L, 24 months after treatment) and reduction in patient 17 
3 (93 nmol/L, 12 months after treatment). Patient 1 did not have CSF neopterins retested after 18 
treatment initiation. Oligoclonal bands were negative. Blood RNA assay showed abnormal 19 
overexpression of ISGs (Figure 3) and raised ALT (maximum 393U/L patient 2) in all patients. ISGs 20 
were repeated in all three patients and have normalized in patients 1 and 2 but remain moderately 21 
abnormal in patient 3 (Figure 3). ALT abnormalities eventually normalized in all patients. RNA 22 
sequencing for viruses in brain biopsy was negative in patients 1 and 2. Liver and muscle biopsies in 23 
patients 1 and 2 revealed no histochemical or enzymatic evidence of mitochondrial disorder. Patient 1 24 
had a low complex IV (0.008; normal range: 0.014-0.034) on respiratory complex enzyme analysis, but 25 
mitochondrial DNA sequencing and analysis for mitochondrial DNA deletion/rearrangements was 26 
negative.  27 
 28 
Genetic testing included whole exome sequencing for patients 1 and 2. This did not show any changes 29 
in the genes known to be responsible for interferonopathies, nuclear genes associated mitochondrial 30 
disorders, neurotransmitter disorders, early onset parkinsonism, dystonia associated disorders and 31 
neurodegeneration with brain iron accumulation. Patient 3 underwent whole genome sequencing also 32 
with no abnormalities identified so far (analysis not yet finalised). Testing for antibodies associated with 33 
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 6 
autoimmune encephalitis and serology screening for infections was negative. All patients had normal 1 
electroencephalograms.  2 
 3 
Patient’s 2 brother presented at 11 months of age (3 months after his sister’s presentation) with an 4 
episode of vomiting and lethargy and was found to have raised ALT of 2000 U/L. The lethargy resolved 5 
within 24 hours and he remained neurologically intact. He was also found to have elevated ISGs tested 6 
acutely. Both his ALT and ISGs normalized after several months (Figure 3). 7 
 8 
Discussion: 9 
We describe three non-related previously well children who presented with a distinct clinical, 10 
immunological and imaging phenotype. All patients presented with subacute deterioration in motor 11 
function with a mixture of dystonia and spasticity, bulbar symptoms including dysphagia and excessive 12 
drooling and regression of speech. None of the patients had seizures. Patients showed similar 13 
biochemical profile with high serum ALT, raised CSF neopterins and abnormal overexpression of 14 
interferon stimulated genes. Additionally, all the patients showed generalized changes mimicking 15 
cerebral atrophy on brain MRI. This presentation could indicate a genetic type 1 interferonopathy, but 16 
all patients were negative for the known genes. Importantly, they demonstrated a clear response to 17 
immunotherapies with complete normalisation of the MRI appearances in all patients and normalization 18 
of ISGs in patients 1 and 2. Patient 2 also showed normalization of CSF neopterins. Patient 3 still has 19 
mildly abnormal ISGs and raised CSF neopterins and therefore she continues on IVIG treatment. The 20 
increased ALT also normalized in all patients after a few months. 21 
 22 
A notable difference between patient 1 and 2 is that brain biopsy in patient 1 showed only evidence of 23 
gliosis whereas biopsy in patient 2 showed clear evidence of inflammation as well as tubuloreticular 24 
inclusions. This may reflect different timings of biopsies from symptom onset. On the other hand, it has 25 
been previously  reported that in severe inflammatory brain disorders gliosis without evidence of 26 
inflammation can be the only histopathologic finding.4 Tubuloreticular inclusions on ultrastructural 27 
examination have been shown to be related to the presence of excessive interferon.5  In addition to 28 
type 1 interferonopathies their presence has been linked to systemic lupus erythematous and viral 29 
infections. No evidence of these conditions was found in our patients. (REF) One cannot exclude the 30 
possibility of a slow infectious encephalitis, from a potential unknown agent (viral or other). However, 31 
the improvement with steroids makes this highly unlikely and deep RNA sequencing for viruses in brain 32 
tissue was negative. 33 
 34 
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 7 
We believe that patient 1’s abnormally low complex IV on respiratory complex analyses is either 1 
secondary or spurious, as complex IV is the most sensitive of the assays to sample handling. 2 
Furthermore, no other evidence of a mitochondrial disorder was found on biochemical or genetic 3 
testing. 4 
 5 
Rasmussen encephalitis presenting with slowly progressing hemiparesis without seizures has been 6 
reported. However, the bilateral presentation seen in our cases makes this diagnosis unlikely6. 7 
A diagnosis of an antibody mediated encephalitis could be considered. The authors believe that this is 8 
also unlikely as no neuronal antibody has been identified and our patients’ prolonged regression is not 9 
typically seen in these disorders7. Nevertheless, the improvement in patient 3 with mainly only IVIG 10 
leaves the possibility of an unidentified antibody mediated encephalitis open. 11 
 12 
All patients were treated with pulse IVMP and IVIG and demonstrated a quick and substantial clinical 13 
improvement in their motor function, bulbar symptoms and expressive language skills in the following 14 
months after treatment. All 3 patients showed relentless deterioration for several months and 15 
improvement was immediately noticed within days of treatment which makes the improvements 16 
observed unlikely to be part of the natural history of this disorder. The mechanisms of action of both 17 
IVIG and steroids may go beyond the known immunosuppressive and immunomodulative effect and 18 
may also be beneficial in patients with primary genetic conditions8 and secondary inflammation9. 19 
 20 
The milder systemic manifestation seen in the brother of patient 2 raised the possibility of an underlying 21 
genetic disorder. Nevertheless, he has remained neurologically asymptomatic over the following years. 22 
Several monogenic disorders mimicking acquired diseases have been described such as RANBP210 23 
and DARS8 and some may respond to immunotherapy. Although the phenotype of our patients is not in 24 
keeping with these known disorders we cannot rule out a yet undiscovered monogenic disorder. 25 
Alternatively, as previously reported in a child with AGS with acquired NMOSD11, these patients could 26 
have two different disorders with an underlying genetic predisposition and a second acquired insult. 27 
 28 
We highlight the importance of evaluating children presenting with neurodegeneration of unknown 29 
aetiology for CNS inflammation, assessing both innate and adaptive immunity biomarkers. 30 
Immunotherapy should be considered in children presenting with this distinct phenotype of subacute 31 
neuroregression, imaging appearances mimicking brain atrophy and evidence of innate immune 32 
activation. This may reverse the course of the disease as exemplified by our cases.  33 
 34 
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Figure 1 capture: 
Brain MRI axial T2 images. A: Case 1 at 32 months (12 months after reported symptom onset): 
Bilateral ventricular and sulcal prominence evidencing volume loss. B: Case 1, 26 months after 
treatment: Complete reversal of previous changes. C: Case 2 at 5 years (5 months after reported 
symptom onset): Generalized volume loss more evident the right cerebral hemisphere. D: Case 
2, 23 months after treatment: Significant reversal of the previously noted appearances of 
ventricular and sulcal prominence. E: Case 3 at 4 years (9 months after reported symptom 
onset): Slight reduction in the cerebral and cerebellar white matter bulk. F: Case 3, 13 months 
after treatment: Improvement of white matter bulk. 
 
Figure 2 capture: 
The figure shows the white matter from Case 2. There is a collection of chronic inflammatory cells 
(A-H&E), confirmed as a mixture of T-cells (B-CD3) and microglia (C-CD68) by 
immunohistochemistry. On ultrastructural examination by electron microscopy (D-EM), there were 
frequent tubuloreticular inclusions (arrow) in the endothelium. Scale bars: A, B & C 100nm D-
500nm 
 
Figure 3 capture: 
Quantitative reverse transcription–polymerase chain reaction of a panel of six interferon 
stimulated genes (ISGs) in whole blood measured in the three patients and the brother of patient 
two compared with healthy control. The relative quantification (RQ) value is equal to 2-∆∆Ct, with 
−∆∆Ct ± SDs (ie, the normalized fold change relative to a calibrator). 
Evidence of marked upregulation of type I interferon signaling was observed in all three patients 
and in patient’s two brother. There was normalization of ISGs in patients 1 and 2 after treatment.  
Age at sampling: Case 1, purple bars: 3 years and 3 months (pre-treatment); 4y8m (post-
treatment). Case 2, red bars:  5y3m; 5y4m; 5y5m; 5y9m (pre-treatment); 6y; 6y2m; 6y10m (post-
treatment). Case 2’s brother, light blue bars: 1y3m; 2y; 2y8m. Case 3, green bars: 4y7m; 5y 
(pre-treatment); 5y3m; 5y7m (post-treatment). Arrows under the X axis indicate treatment 
initiation. 
 
Video 1 capture 
Video 1: A video clip of the patient in Case 1 taken in four different time points. First clip at age 
two years and eleven months shows dystonic posturing of both upper limbs and difficulty to grasp 
objects. He also had some degree of axial hypotonia with curving of the spine. Second clip at 
age four years with obvious dystonic posturing and movements of all four limbs with both feet on 
equinovarus position. Third and fourth clip at age four years and a half after treatment shows 
him playing with toy and tablet computer with better upper limb posturing, grasp and fine motor 
skills.  
 
Video 2 capture 
Video 2: A video clip of the patient in Case 2 taken in two different time points. First clip at age 
six years and six months after treatment was started still presenting with abnormal gait pattern 
with increased tone and bilateral dragging her feet more marked on the left side (this was already 
improved compared to presentation). Second and third clips at age eight years walking up and 
down the stairs independently with an improved gait and riding a bicycle without any difficulties. 
 
Video 3 capture: 
Video 3: A video clip of the patient in Case 3 taken in four different time points. First clip at age 
four years mainly showing the complete loss of expressive speech. Second clip at age four 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
years and six months shows a spastic/dystonic gait characterized by a wide base, hyperextended 
knees and feet posture into equinovarus. She was only able to walk independently for a few 
seconds. Third clip at age five years and eleven months shows some dystonic posturing while 
grasping but already with significant improvement compared to pre-treatment state. Fourth clip 
at age six years and four months shows her independent gait with internal rotation of both feet, 
more noticeable on the right side. 
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 Case 1 Case 2 Case 3 
Brain MRI Progressive right hemispheric evolving to 
global symmetric volume loss. 
Two years after treatment: complete reversal 
of changes. 
Generalized cerebral volume loss more 
marked in the right cerebral hemisphere. 
Three years after treatment: reversal of MRI 
changes. 
Mild reduction in the cerebral and cerebellar 
white matter bulk and some delay in 
maturation of myelin. 
One year after treatment: reversal of 
previous volume loss. 
Brain histology Patchy gliosis with good neuronal 
preservation and no significant inflammation. 
Perivascular lymphocytes; focal collections 
of inflammatory cells in the white matter. 
Ultrastructural examination: frequent 
tubuloreticular inclusions in the endothelium. 
 --- 
Serum ALT maximum: 90 U/L ALT maximum: 393 U/L ALT maximum: 37 U/L 
CSF neopterin 240 and 355 nmol/L (7-65 nmol/L), not 
repeated after treatment 
200 nmol/L (7-65 nmol/L), repeated 24 
months after treatment: 29 nmol/L 
151 nmol/L (7-65 nmol/L), repeated 12 
months after treatment: 93 nmol/L  
Genetics Whole exome sequencing: no changes to the genes responsible for interferonopathies, 
mitochondrial disorders, neurotransmitter disorders, early onset parkinsonism, dystonia 
disorders and neurodegeneration with brain iron accumulation.  
Whole genome sequencing ongoing: no 
changes identified so far. 
No mutations found on gene panel 
sequencing TREX1, ADAR1, 
RNASEH2A/B/C, IFIH1, SAMHD1. 
--- 
Other 
investigations 
All patients showed: no cells, normal proteins in CSF; oligoclonal bands negative in serum and CSF; testing for antibodies associated with 
autoimmune encephalitis and serology screening for infections negative; normal electroencephalograms.   
Liver and muscle biopsies: normal, low complex IV in patient 1 (muscle), see text --- 
Treatment 18 months from clinical presentation: 
- IV Methylprednisolone (30mg/kg), 6 weekly 
pulses followed by IV Immunoglobulin 
(2g/kg), monthly. 
12 months from clinical presentation: 
- IV Methylprednisolone (30mg/kg, 5 days) 
and IV Immunoglobulin (2g/kg), 4 cycles, 3 
months apart. 
15 months from clinical presentation: 
- IV Methylprednisolone (30mg/kg, 3 days) 
only once, followed by IV Immunoglobulin 
(2g/kg), 5 cycles over 20 months, ongoing. 
Outcome Improvement mainly in fine motor, non-
verbal communication. Also, gross motor 
skills and speech. Able to sit unsupported 
and gaining new vocabulary. 
Significant improvement in movement 
disorder and in all domains of function: gross 
motor, fine motor and speech. 
Improvement in lower limb tone, motor and 
expressive language skills. Now able to 
climb stairs unaided, produce three to four 
word sentences, behavior also normalised 
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E
F
D
D
C
5 months 9 months
Time from reported symptom onset
23 months
(35 months)
13 months
(30 months)
B
26 months
(44 months)
12 months
Time from treatment start
(time from reported symptom onset)
A
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